Patents by Inventor Masamichi Sugimoto
Masamichi Sugimoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230146730Abstract: The invention provides biomarkers for predicting the response to checkpoint inhibitors. The inventors demonstrate that a PD-1/PD-L1 inhibitor exerts antitumor activity against tumor with low PD-L1 expression and immune-desert phenotype through blocking PD-L1 in the lymph nodes. The invention provides novel combinations of intratumoral markers for antigen cross-presenting cells and T cell chemokines which are expected to be superior efficacy-predicting biomarkers compared to existing methods.Type: ApplicationFiled: March 19, 2021Publication date: May 11, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Toshiki Iwai, Masamichi Sugimoto
-
Publication number: 20230091221Abstract: The present invention relates to a pharmaceutical composition comprising an anti-PD-L1 antibody as an active ingredient, wherein the pharmaceutical composition is used in combination with camptothecin and/or a derivative thereof, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 28, 2022Publication date: March 23, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Toshiki Iwai, Kaname Yamamoto, Masamichi Sugimoto
-
Publication number: 20210388090Abstract: The present invention relates to medicaments, treatment methods, kits, and uses for treating cancer in individuals, characterized in that a VEGF signaling inhibitor and a PD-1/PD-L1 signaling inhibitor are administered in combination, as well as VEGF signaling inhibitors, PD-1/PD-L1 signaling inhibitors, and combinations thereof.Type: ApplicationFiled: October 17, 2019Publication date: December 16, 2021Inventors: Nobuyuki ISHIKURA, Toshiki IWAI, Masamichi SUGIMOTO
-
Publication number: 20210198364Abstract: The present invention relates to a pharmaceutical composition comprising an anti-PD-L1 antibody as an active ingredient, wherein the pharmaceutical composition is used in combination with camptothecin and/or a derivative thereof, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 26, 2018Publication date: July 1, 2021Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Toshiki Iwai, Kaname Yamamoto, Masamichi Sugimoto
-
Patent number: 10118959Abstract: An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. Since the Fc-modified anti-glypican-3 antibody of the invention exhibit enhanced ADCC activity, it is useful in treating cancers, such as hepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention.Type: GrantFiled: October 3, 2014Date of Patent: November 6, 2018Assignees: Chugai Seiyaku Kabushiki Kaisha, Xencor, Inc.Inventors: Gregory Alan Lazar, Bassil I. Dahiyat, Hisafumi Okabe, Masamichi Sugimoto, Shigeyuki Iijima, Izumi Sugo
-
Patent number: 9102739Abstract: An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. Since the Fc-modified anti-glypican-3 antibody of the invention exhibit enhanced ADCC activity, it is useful in treating cancers, such as hepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention.Type: GrantFiled: October 11, 2006Date of Patent: August 11, 2015Assignees: Chugai Seiyaku Kabushiki Kaisha, Xencor, Inc.Inventors: Gregory Alan Lazar, Bassil I. Dahiyat, Hisafumi Okabe, Masamichi Sugimoto, Shigeyuki Iijima, Izumi Sugo
-
Publication number: 20150098941Abstract: An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. Since the Fc-modified anti-glypican-3 antibody of the invention exhibit enhanced ADCC activity, it is useful in treating cancers, such as hepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention.Type: ApplicationFiled: October 3, 2014Publication date: April 9, 2015Applicants: CHUGAI SEIYAKU KABUSHIKI KAISHA, XENCOR, INC.Inventors: Gregory Alan Lazar, Bassil I. Dahiyat, Hisafumi Okabe, Masamichi Sugimoto, Shigeyuki Iijima, Izumi Sugo
-
Patent number: 8663929Abstract: The present invention relates to an in-vitro immunoassay method for detecting the presence of liver cancer cells in a subject. In the method of the present invention, antigen retrieval treatment based on heat-induced epitope retrieval method and antigen retrieval treatment based on protease-induced epitope retrieval method can be combined in the detection of glypican 3 antigen expression in liver cancer tissues to thereby detect the difference in the expression level or expression pattern of the glypican 3 antigen by immunohistochemical staining method. This enables samples, which has been determined by the conventional HIER method as highly expressing glypican 3, to be graded according to the expression level of glypican 3.Type: GrantFiled: March 16, 2009Date of Patent: March 4, 2014Assignees: University of Miyazaki, Chugai Seiyaku Kabushiki KaishaInventors: Hiroaki Kataoka, Hirotake Takai, Atsuhiko Kato, Masami Suzuki, Masamichi Sugimoto
-
Patent number: 8597644Abstract: A method for treating psoriasis comprising an interleukin-6 (IL-6) antagonist such as, for example, an antibody against IL-6 receptor.Type: GrantFiled: November 29, 2007Date of Patent: December 3, 2013Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Hiroaki Ito, Kazuyuki Yoshizaki, Norihiro Nishimoto, Tadamitsu Kishimoto, Shin Shimaoka, Hidetomo Kitamura, Masamichi Sugimoto, Kenichi Akamatsu
-
Patent number: 8562990Abstract: A method for treating psoriatic arthritis comprising an interleukin-6 (IL-6) antagonist such as, for example, an antibody against IL-6 receptor.Type: GrantFiled: June 15, 2011Date of Patent: October 22, 2013Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Hiroaki Ito, Kazuyuki Yoshizaki, Norihiro Nishimoto, Tadamitsu Kishimoto, Shin Shimaoka, Hidetomo Kitamura, Masamichi Sugimoto, Kenichi Akamatsu
-
Publication number: 20110268734Abstract: A method for treating psoriatic arthritis comprising an interleukin-6 (IL-6) antagonist such as, for example, an antibody against IL-6 receptor.Type: ApplicationFiled: June 15, 2011Publication date: November 3, 2011Inventors: Hiroaki Ito, Kazuyuki Yoshizaki, Norihiro Nishimoto, Tadamitsu Kishimoto, Shin Shimaoka, Hidetomo Kitamura, Masamichi Sugimoto, Kenichi Akamatsu
-
Publication number: 20110104157Abstract: A novel pharmaceutical composition for treating or preventing hepatocellular carcinoma and a method of treatment are provided. A pharmaceutical composition for treating or preventing liver cancer is obtained by combining a chemotherapeutic agent with an anti-glypican 3 antibody. Also disclosed is a pharmaceutical composition for treating or preventing liver cancer which comprises as an active ingredient an anti-glypican 3 antibody for use in combination with a chemotherapeutic agent, or which comprises as an active ingredient a chemotherapeutic agent for use in combination with an anti-glypican 3 antibody. Using the chemotherapeutic agent and the anti-glypican 3 antibody in combination yields better therapeutic effects than using the chemotherapeutic agent alone, and mitigates side effects that arise from liver cancer treatment with the chemotherapeutic agent.Type: ApplicationFiled: March 19, 2009Publication date: May 5, 2011Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Yasuko Kinoshita, Masamichi Sugimoto, Takahiro Ishiguro
-
Publication number: 20110091907Abstract: The present invention relates to an in-vitro immunoassay method for detecting the presence of liver cancer cells in a subject. In the method of the present invention, antigen retrieval treatment based on heat-induced epitope retrieval method and antigen retrieval treatment based on protease-induced epitope retrieval method can be combined in the detection of glypican 3 antigen expression in liver cancer tissues to thereby detect the difference in the expression level or expression pattern of the glypican 3 antigen by immunohistochemical staining method. This enables samples, which has been determined by the conventional HIER method as highly expressing glypican 3, to be graded according to the expression level of glypican 3.Type: ApplicationFiled: March 16, 2009Publication date: April 21, 2011Applicants: University of Miyazaki, Chugai Seiyaku Kabushiki KaishaInventors: Hiroaki Kataoka, Hirotake Takai, Atsuhiko Kato, Masami Suzuki, Masamichi Sugimoto
-
Publication number: 20110033452Abstract: An anti-glypican 3 antibody with modified sugar chains, more specifically, an anti-glypican 3 antibody lacking fucose is provided. The anti-glypican 3 antibody with modified sugar chains of the present invention may be produced by a process comprising introducing a nucleic acid encoding an anti-glypican 3 antibody into host cells with reduced fucose addition capability, such as YB2/0 cells and cells lacking a fucose transporter. The anti-glypican 3 antibody with modified sugar chains of the present invention has a high level of cytotoxic activity and therefore is useful as a cell growth inhibitor such as an anticancer agent.Type: ApplicationFiled: August 9, 2010Publication date: February 10, 2011Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Kiyotaka Nakano, Izumi Sugo, Masamichi Sugimoto, Takahiro Ishiguro, Megumi Tanaka, Shigeyuki Iijima
-
Patent number: 7871613Abstract: The present invention provides an anti-cancer agent comprising anti-glypican 3 antibody wherein the anti-cancer agent is administered after a cancer treatment, Preferably, after a cancer treatment is after a treatment for liver cancer, and the treatment for liver cancer is in particular a resection of liver cancer cells. The anti-cancer agent according to the present invention is preferably administered if glypican 3 is expressed in the resected liver cancer cells. The anti-glypican 3 antibody is preferably a monoclonal antibody. The anti-cancer agent according to the present invention is useful for preventing cancer and for preventing the recurrence of cancer.Type: GrantFiled: August 23, 2005Date of Patent: January 18, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Yasuko Kinoshita, Masamichi Sugimoto, Hisafumi Okabe
-
Patent number: 7867734Abstract: An anti-glypican 3 antibody with modified sugar chains, more specifically, an anti-glypican 3 antibody lacking fucose is provided. The anti-glypican 3 antibody with modified sugar chains of the present invention may be produced by a process comprising introducing a nucleic acid encoding an anti-glypican 3 antibody into host cells with reduced fucose addition capability, such as YB2/0 cells and cells lacking a fucose transporter. The anti-glypican 3 antibody with modified sugar chains of the present invention has a high level of cytotoxic activity and therefore is useful as a cell growth inhibitor such as an anticancer agent.Type: GrantFiled: October 26, 2005Date of Patent: January 11, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Kiyotaka Nakano, Izumi Sugo, Masamichi Sugimoto, Takahiro Ishiguro, Megumi Tanaka, Shigeyuki Iijima
-
Publication number: 20090061485Abstract: The present invention relates to a method of producing a recombinant protein, particularly an antibody, using a cell in which the function of a fucose transporter is inhibited, and it also provides a cell in which the expression of fucose transporter genes on both homologous chromosomes is artificially suppressed.Type: ApplicationFiled: December 22, 2004Publication date: March 5, 2009Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Masayuki Tsuchiya, Shigeyuki Iijima, Izumi Sugo, Yasuo Sekimori, Kiyoshi Habu, Masamichi Sugimoto
-
Publication number: 20080267979Abstract: An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. Since the Fc-modified anti-glypican-3 antibody of the invention exhibit enhanced ADCC activity, it is useful in treating cancers, such as hepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention.Type: ApplicationFiled: October 11, 2006Publication date: October 30, 2008Inventors: Gregory Alan Lazar, Bassil I. Dahiyat, Hisafumi Okabe, Masamichi Sugimoto, Shigeyuki Iijima, Izumi Sugo
-
Publication number: 20080166756Abstract: The present invention relates to a method of producing a recombinant protein particularly an antibody using a cell in which the function of a fucose transporter is inhibited. According to the present invention, a cell in which the expression of fucose transporter genes on both homologous chromosomes is artificially suppressed is provided.Type: ApplicationFiled: October 26, 2005Publication date: July 10, 2008Inventors: Masayuki Tsuchiya, Shigeyuki IIjima, Izumi Sugo, Yasuo Sekimori, Kiyoshi Habu, Masamichi Sugimoto
-
Publication number: 20080124330Abstract: An anti-glypican 3 antibody with modified sugar chains, more specifically, an anti-glypican 3 antibody lacking fucose is provided. The anti-glypican 3 antibody with modified sugar chains of the present invention may be produced by a process comprising introducing a nucleic acid encoding an anti-glypican 3 antibody into host cells with reduced fucose addition capability, such as YB2/0 cells and cells lacking a fucose transporter. The anti-glypican 3 antibody with modified sugar chains of the present invention has a high level of cytotoxic activity and therefore is useful as a cell growth inhibitor such as an anticancer agent.Type: ApplicationFiled: October 26, 2005Publication date: May 29, 2008Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Kiyotaka Nakano, Izumi Sugo, Masamichi Sugimoto, Takahiro Ishiguro, Megumi Tanaka, Shigeyuki Iijima